Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Ravasio, Roberto
239  Ergebnisse:
Personensuche X
?
1

Caloric restriction leads to druggable LSD1-dependent cance..:

Pallavi, Rani ; Gatti, Elena ; Durfort, Tiphanie...
Nature Communications.  15 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
2

Cost per NNT for upadacitinib in the treatment of patients ..:

Chiricozzi, Andrea ; Costanzo, Antonio ; Levi, Anna..
Global and Regional Health Technology Assessment.  11 (2024)  1 - p. 38-50 , 2024
Link: https://doi.org/10.33393..
 
?
3

Expert Insights from a Delphi-driven Neurologists' Panel: R..:

Lidonnici, Dario ; Brambilla, Pietro ; Ravasio, Roberto...
Journal of Neuromuscular Diseases.  11 (2024)  2 - p. 411-423 , 2024
Link: https://doi.org/10.3233/..
 
?
4

Economic evaluation of two therapeutic sequences in the fir..:

Armeni, Patrizio ; Compagnucci, Elena ; Fiorino, Gionata...
AboutOpen.  11 (2024)  1 - p. 21-29 , 2024
Link: https://doi.org/10.33393..
 
?
5

Budget impact analysis of natalizumab biosimilar on pharmac..:

Bergamaschi, Roberto ; Capobianco, Marco ; Ravasio, Roberto
AboutOpen.  11 (2024)  1 - p. 48-56 , 2024
Link: https://doi.org/10.33393..
 
?
6

Cost per Number Needed to Treat (NNT) for upadacitinib in t..:

Caprioli, Flavio ; Fantini, Massimo Claudio ; Marando, Francesca..
Global and Regional Health Technology Assessment.  11 (2024)  1 - p. 55-67 , 2024
Link: https://doi.org/10.33393..
 
?
7

Cost-minimization analysis of HYQVIA® in the treatment of p..:

Ravasio, Roberto ; Ripoli, Silvia
AboutOpen.  10 (2023)  - p. 69-77 , 2023
Link: https://doi.org/10.33393..
 
?
8

A new cost-utility analysis assessing risk factor-guided pr..:

Keary, Ian P. ; Ravasio, Roberto ; Fullarton, John R....
PLOS ONE.  18 (2023)  8 - p. e0289828 , 2023
Link: https://doi.org/10.1371/..
 
?
9

Cost per responder for vedolizumab and ustekinumab in Crohn..:

Ravasio, Roberto ; Viti, Raffaella ; Roscini, Antonio Saverio
AboutOpen.  10 (2023)  - p. 13-21 , 2023
Link: https://doi.org/10.33393..
 
?
10

The costs incurred by patients to get eligibility to PCSK9 ..:

Bertolani, Arianna ; Ravasio, Roberto ; Raimondo, Paola.
Global & Regional Health Technology Assessment.  9 (2022)  - p. 73-81 , 2022
Link: https://doi.org/10.33393..
 
?
11

Treatment management of patients with systemic lupus erythe..:

Sebastiani, Gian Domenico ; Mosca, Marta ; Ravasio, Roberto...
Global & Regional Health Technology Assessment.  9 (2022)  - p. 123-132 , 2022
Link: https://doi.org/10.33393..
 
?
12

Cost-utility analysis of brigatinib compared to alectinib i..:

Ravasio, Roberto ; Cranmer, Holly ; Kearns, Izzie..
AboutOpen.  9 (2022)  - p. 92-104 , 2022
Link: https://doi.org/10.33393..
 
?
13

Erratum in: Cost per responder for upadacitinib vs abatacep..:

Caporali, Roberto ; Ravasio, Roberto ; Raimondo, Paola.
Global & Regional Health Technology Assessment.  9 (2022)  - p. 30 , 2022
Link: https://doi.org/10.33393..
 
?
14

Number needed to treat for interleukin inhibitors approved ..:

Ravasio, Roberto ; Costanzo, Antonio ; Antonelli, Silvia..
Global & Regional Health Technology Assessment.  8 (2021)  - p. 53-57 , 2021
Link: https://doi.org/10.33393..
 
?
15

Cost-effectiveness analysis of caplacizumab in the new stan..:

Di Minno, Giovanni ; Ravasio, Roberto
Global & Regional Health Technology Assessment.  8 (2021)  - p. 43-52 , 2021
Link: https://doi.org/10.33393..
 
1-15